Download PDF
Horm Metab Res 2015; 47(11): 861-865
DOI: 10.1055/s-0034-1398564
Endocrine Research
© Georg Thieme Verlag KG Stuttgart · New York

Glargine Promotes Human Colorectal Cancer Cell Proliferation via Upregulation of miR-95

J. Qin
1   Department of Radiation Oncology of Clinical Cancer Center, The People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning, China
,
J.-A. Teng
2   Department of Cadre Medicine, Division of Endocrinology and Metabolism, The People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning, China
,
Z. Zhu
3   Department of Gastrointestinal and Peripheral Vascular Surgery, The People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning, China
,
J.-X. Chen
1   Department of Radiation Oncology of Clinical Cancer Center, The People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning, China
,
Y.-Y. Wu
4   Department of Pharmacology, School of Pharmacy, Chengdu Medical College, Chengdu, China
› Author Affiliations
Further Information

Publication History

received 16 November 2014

accepted 18 December 2014

Publication Date:
11 February 2015 (online)

Also available at
    Permissions and Reprints

Abstract

Several studies have shown a correlation between glargine use and cancer risk. However, the role of glargine in carcinogenesis, especially in colorectal cancer (CRC), is still inconclusive. The aim of this study was to investigate the influence of glargine on proliferation of CRC cells and its possible mechanism. Effect of glargine on the cell proliferation was tested in HCT-116 and SW480 cells by MTT assay, and apoptosis was measured by flow cytometry. The expression of microRNA-95 (miR-95) and sorting nexin 1 (SNX1) protein was also determined by real-time PCR and Western blotting, respectively. The results showed that high dose glargine (from 150 to 300 nM) promoted proliferation and inhibit2ed apoptosis of CRC cells compared with untreated cells. Moreover, glargine could upregulate miR-95 and downregulate SNX1 protein expression in CRC cells. These data show that glargine may indeed trigger cellular proliferation in CRC, probably by regulating miR-95.

Key words

glargine - miR-95 - SNX1 - colorectal cancer
 

  • References

  • 1 Lucidi P, Porcellati F, Rossetti P, Candeloro P, Andreoli AM, Cioli P, Hahn A, Schmidt R, Bolli GB, Fanelli CG. Metabolism of insulin glargine after repeated daily subcutaneous injections in subjects with type 2 diabetes. Diabetes Care 2012; 35: 2647-2649
    CrossrefPubMedSearch in Google Scholar
  • 2 Tang X, Yang L, He Z, Liu J. Insulin glargine and cancer risk in patients with diabetes: a meta-analysis. PLoS One 2012; 7: e51814
    CrossrefPubMedSearch in Google Scholar
  • 3 Hemkens LG, Grouven U, Bender R, Günster C, Gutschmidt S, Selke GW, Sawicki PT. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009; 52: 1732-1744
    CrossrefPubMedSearch in Google Scholar
  • 4 Colhoun HM. SDRN Epidemiology Group . Use of insulin glargine and cancer incidence in Scotl and: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 2009; 52: 1755-1765
    CrossrefPubMedSearch in Google Scholar
  • 5 Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdòttir S, Steineck G. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 2009; 52: 1745-1754
    CrossrefPubMedSearch in Google Scholar
  • 6 Mannucci E, Monami M, Balzi D, Cresci B, Pala L, Melani C, Lamanna C, Bracali I, Bigiarini M, Barchielli A, Marchionni N, Rotella CM. Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 2010; 33: 1997-2003
    CrossrefPubMedSearch in Google Scholar
  • 7 Chen YB, Chen Q, Wang Z, Zhou J. Insulin Therapy and Risk of Prostate Cancer: a Systematic Review and Meta-Analysis of Observational Studies. PLoS One 2013; 8: e81594
    CrossrefPubMedSearch in Google Scholar
  • 8 Fagot JP, Blotière PO, Ricordeau P, Weill A, Alla F, Allemand H. Does insulin glargine increase the risk of cancer compared with other basal insulins?: A French nationwide cohort study based on national administrative databases. Diabetes Care 2013; 36: 294-301
    CrossrefPubMedSearch in Google Scholar
  • 9 Karlstad O, Starup-Linde J, Vestergaard P, Hjellvik V, Bazelier MT, Schmidt MK, Andersen M, Auvinen A, Haukka J, Furu K, de Vries F, De Bruin ML. Use of insulin and insulin analogs and risk of cancer – systematic review and meta-analysis of observationalstudies. Curr Drug Saf 2013; 8: 333-348
    CrossrefPubMedSearch in Google Scholar
  • 10 Lim S, Stember KG, He W, Bianca PC, Yelibi C, Marquis A, Stürmer T, Buse JB, Meigs JB. Electronic Medical Record Cancer Incidence over Six Years Comparing New Users of Glargine with New Users of NPH Insulin. PLoS One 2014; 9: e109433
    CrossrefPubMedSearch in Google Scholar
  • 11 Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H. Insulin analogues display IGF-1-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes Metab Res Rev 2009; 25: 41-49
    CrossrefPubMedSearch in Google Scholar
  • 12 Nagel JM, Staffa J, Renner-Müller I, Horst D, Vogeser M, Langkamp M, Hoeflich A, Göke B, Kolligs FT, Mantzoros CS. Insulin glargine and NPH insulin increase to a similar degree epithelial cell proliferation and aberrant crypt foci formation in colons of diabetic mice. Horm Cancer 2010; 1: 320-330
    CrossrefPubMedSearch in Google Scholar
  • 13 Hauptman N, Glavac D. MicroRNAs and long non-coding RNAs: prospects in diagnostics and therapy of cancer. Radiol Oncol 2013; 47: 311-318
    PubMedSearch in Google Scholar
  • 14 Jansson MD, Lund AH. MicroRNA and cancer. Mol Oncol 2012; 6: 590-610
    CrossrefPubMedSearch in Google Scholar
  • 15 Li WG, Yuan YZ, Qiao MM, Zhang YP. High dose glargine alters the expression profiles of microRNAs in pancreatic cancer cells. World J Gastroenterol 2012; 18: 2630-2639
    CrossrefPubMedSearch in Google Scholar
  • 16 Huang Z, Huang S, Wang Q, Liang L, Ni S, Wang L, Sheng W, He X, Du X. MicroRNA-95 promotes cell proliferation and targets sorting Nexin 1 in human colorectal carcinoma. Cancer Res 2011; 71: 2582-2589
    CrossrefPubMedSearch in Google Scholar
  • 17 Huang X, Taeb S, Jahangiri S, Emmenegger U, Tran E, Bruce J, Mesci A, Korpela E, Vesprini D, Wong CS, Bristow RG, Liu FF, Liu SK. miRNA-95 mediates radioresistance in tumors by targeting the sphingolipid phosphatase SGPP1. Cancer Res 2013; 73: 6972-6986
    CrossrefPubMedSearch in Google Scholar
  • 18 Chen X, Chen S, Hang W, Huang H, Ma H. MiR-95 induces proliferation and chemo- or radioresistance through directly targeting sorting nexin1 (SNX1) in non-small cell lung cancer. Biomed Pharmacother 2014; 68: 589-595
    CrossrefPubMedSearch in Google Scholar
  • 19 Nguyen LN, Holdren MS, Nguyen AP, Furuya MH, Bianchini M, Levy E, Mordoh J, Liu A, Guncay GD, Campbell JS, Parks WT. Sorting nexin 1 down-regulation promotes colon tumorigenesis. Clin Cancer Res 2006; 12: 6952-6959
    CrossrefPubMedSearch in Google Scholar
  • 20 Varkonyi-Gasic E, Hellens RP. Quantitative stem-loop RT-PCR for detection of microRNAs. Methods Mol Biol 2011; 744: 145-157
    PubMedSearch in Google Scholar
  • 21 Sciacca L, Le Moli R, Vigneri R. Insulin analogs and cancer. Front Endocrinol (Lausanne) 2012; 3: 21
    PubMedSearch in Google Scholar
  • 22 Liu SY, Liang Y, Lin TX, Su F, Liang WW, Uwe H, Li Y. MEK1 and MEK2 differentially regulate human insulin- and insulin glargine-induced human bladder cancer T24cell proliferation. Chin Med J (Engl) 2012; 125: 4197-4201
    PubMedSearch in Google Scholar
  • 23 Teng JA, Hou RL, Li DL, Yang RP, Qin J. Glargine promotes proliferation of breast adenocarcinoma cell line MCF-7 via AKT activation. Horm Metab Res 2011; 43: 519-523
    Thieme ConnectPubMedSearch in Google Scholar